Further research is needed to identify predictive biomarkers for certain cancers, results suggest
San Francisco, CA (UroToday.com) — A high rate of genetic mutations within a tumor, known as high tumor mutation burden (TMB), was only useful for predicting clinical responses to immune checkpoint inhibitors in a subset of cancer types, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.